Neil Stahl, EVP Research and Development at REGENERON PHARMACEUTICALS INC (REGN), sold 20,000 shares at $521.70 ($10.4M) on 2017-06-22, disclosed to the SEC on 2017-06-23.
Open-market sale of $10.4M REGN by EVP Research and Development. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $510.02 | 1,201 | $613K | 5.9% |
| 2 | $510.02 | 10,493 | $5.4M | 51.5% |
| 3 | $521.70 | 100 | $52K | 0.5% |
| 4 | $522.80 | 200 | $105K | 1.0% |
| 5 | $523.52 | 200 | $105K | 1.0% |
| 6 | $524.08 | 101 |
| $53K |
| 0.5% |
| 7 | $525.10 | 400 | $210K | 2.0% |
| 8 | $526.45 | 600 | $316K | 3.0% |
| 9 | $529.61 | 100 | $53K | 0.5% |
| 10 | $530.64 | 800 | $425K | 4.1% |
| 11 | $531.42 | 900 | $478K | 4.6% |
| 12 | $532.44 | 500 | $266K | 2.6% |
| 13 | $533.49 | 905 | $483K | 4.6% |
| 14 | $534.64 | 700 | $374K | 3.6% |
| 15 | $535.37 | 800 | $428K | 4.1% |
| 16 | $536.46 | 800 | $429K | 4.1% |
| 17 | $537.42 | 200 | $107K | 1.0% |
| 18 | $538.39 | 600 | $323K | 3.1% |
| 19 | $539.36 | 200 | $108K | 1.0% |
| 20 | $540.04 | 100 | $54K | 0.5% |
| 21 | $541.70 | 100 | $54K | 0.5% |
| Total | $519.38 avg | 20,000 | $10.4M | 100% |
| Filing → |
| REGN | SELL | 2023-08-23 | $19.6M | — | Filing → |
| REGN | SELL | 2022-08-08 | $28.4M | — | Filing → |
| REGN | SELL | 2021-05-18 | $18.2M | — | Filing → |